At the Crossroads of Coagulation

Slides:

Advertisements

Similar presentations

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

Advertisements

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

NOACs for Cancer-Associated Thrombosis:

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

US Guidelines US Guidelines Low-risk Patients.

Thrombosis, Cancer, and NOACs

A CASE CHALLENGE IN HFrEF:

The ABCs of AF.

NOACs in Clinical Practice: Are They All the Same?

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Emergency Management of NOAC Bleeding

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Oral Anticoagulants in AFa,b A Brief History.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

A Case Challenge: Anticoagulant Choices for Acute PE

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

Evaluation of the Patient With HCV Infection

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Is RA Treatment Addressing the Real Needs of Patients?

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Oral Anticoagulation in AF

Real-World Evidence in VTE

Mutational Testing to Select Novel Targeted Therapies in AML

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

NOACs in AF: Consequences of Underdosing and NonAdherence

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

Extraordinary Cases in VTE

Program Goals Background: Anticoagulation in Patients With VTE.

NOACs in AF: Consequences of Underdosing and NonAdherence

Assessing the Burden of Hyperkalemia

The ABCs of AF.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

AMD Therapy: Where Are We Now and Where Are We Going?

Assessing the Burden of Hyperkalemia

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

The Building Blocks of Homocystinuria and Homocysteinemia Management

Treatment Advances for RA

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

Extraordinary Cases in Stroke Prevention

Treating Pulmonary Embolism Today

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Presentation transcript:

At the Crossroads of Coagulation

VTE A Ubiquitous Disease Seen…

Disease Burden of VTE

VTE

Patient Presentation With PE

Low/Intermediate Probability of PE

sPESI Score for Assessing the Likelihood of PE-Related Death

Predicting Mortality in Acute PE Imaging and Laboratory Tests

Risk Parameters and Scores in Acute PE Based on Intermediate Risk of Mortality

NOACs: VTE Acute Treatment Trials

NOACs: VTE Acute Treatment Trial Designs

Hokusai-VTE RVD and Recurrent VTE

Hokusai-VTE Safety in PE Patients With RVD

2014 ESC Guidelines Treatment of Acute PE

Heparin Lead-In Diagnostic Phase

NOAC Dosing Considerations in VTE

Summary

Abbreviations

Abbreviations (cont)